The Company plans to initiate a Phase 1 study of MRT-8102 in the coming weeks and anticipates sharing initial results in H1 2026. “The IND clearance of MRT-8102 is another important milestone in ...

MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical ...

Monte Rosa Therapeutics, Inc. a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, announced US Food and Drug Administration (FDA) clearance of an ...

MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa's clinical I&I ...

(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) announced FDA clearance of an Investigational New Drug application for MRT-8102, a NEK7-directed MGD being developed for the treatment of ...

ANN ARBOR, Mich. (AP) — The University of Michigan said it’s cutting ties with a private security company that was accused of following pro-Palestinian activists on and off campus. The ...

Denny Hamlin couldn’t help himself. He brought it back after winning the NASCAR Cup Series race at Michigan International Speedway on Sunday afternoon. "Daddy, I'm sorry, but I beat your ...

It sure seemed like it at times in Game 1 of the series, anyway — and odds are, there will be more of those moments throughout the rest of this matchup between the Pacers and Thunder. There are four ...

Bill Oxford/E+ via Getty Images Monte Rosa Therapeutics (NASDAQ:GLUE) said on Tuesday that the U.S. FDA approved the request to start testing its orally active molecular glue degrader, MRT-8102 ...